European Collaborations
Navigate Up
Sign In

European Collaborations

Through the various European collaborations: exchange of information, best practices/policies and experiences about Pharmaceutical Policies on Pricing and Reimbursement of pharmaceuticals, Health Technology Assessment and other pharmaceutical issues are identified, shared and discussed.
The Directorate participates in various EU projects involving sharing of information related to pharmaceutical policies, pricing and reimbursement of medicine, between the participating member states.
DPA aims:
·     To participate in various EU networks and initiatives relating to Pharmaceutical Policy; 
·     To communicate with other EU peers involved in similar functions;
·     To establish contacts with Pricing and Reimbursement Agencies and Authorities in the various EU countries aimed at continual improvements of various aspects of Pharmaceutical Policy in Malta.
EUnetHTA and the HTA Network
The Directive 2011/24/EU on the application of patients’ rights in cross-border healthcare was adopted in 2011 and stipulates (Article 15) that the Union shall support and facilitate cooperation between national authorities or bodies responsible for health technology assessment designated by the Member States. According to the Implementing Decision, the HTA Network is to be supported by a scientific and technical cooperation to meet the objectives of the European cooperation on HTA as per Article 15 of the Directive.  
  •  Health Technology Assessment (HTA) Network
HTA is an important part of evidence-based health decision-making in most EU countries.   To enhance cooperation between countries, the Commission:
·         has set up a permanent, voluntary HTA network in Europe. The network aims to:
-  facilitate efficient use of HTA resources in Europe
-  create a sustainable system of HTA knowledge sharing
-  promote good practice in HTA methods and processes
·         supports EUnetHTA's Joint Action 3 on HTA, with funding from the EU health programme:
       EUnetHTA – European network for Health Technology Assessment
The HTA Network met for the first time in October 2013. All Member States have appointed a representative.
Logo of European network for Health Technology Assessment
  • European Network for Health Technology Assessment (EUnetHTA)
EUnetHTA performs the function of the scientific and technical cooperation of the HTA Network.
EUnetHTA was established to create an effective and sustainable network for HTA across Europe – to help develop reliable, timely, transparent and transferable information to contribute to HTAs in European countries.
EUnetHTA supports collaboration between European HTA organisations that bring added value at the European, national and regional level through
·         facilitating efficient use of resources available for HTA
·         creating a sustainable system of HTA knowledge sharing
·         promoting good practice in HTA methods and processes.
EUnetHTA consists of a total of 78 organisations (61 Partners, 16 Affiliates and 1 Associate) from 28 EU member states plus Norway and Switzerland.
DPA has been collaborating in this joint action since 2010 in the EUnetHTA Joint Action 1 (2010-2012) programme activities, Joint Action 2 (2012-2015) and will continue its participation in the Joint Action 3 till the end of the project which is scheduled till 2020.  

The Pharmaceutical Pricing and Reimbursement Information (PPRI) network Logo of Pharmaceutical Pricing and Reimbursement Information

The Pharmaceutical Pricing and Reimbursement Information (PPRI) is a networking and information-sharing initiative on burning issues of pharmaceutical policies from a public health perspective. It involves a network of more than 90 institutions (the relevant competent authorities and third party payers) from 46, mainly European, countries, thereof all 28 European Union Member States, and European and international institutions (e.g. WHO, OECD and European Commission services and agencies). Since 2008, PPRI has been a member state driven and sustainable initiative.
The PPRI was established in 2005 with the aim to offer a platform for competent authorities of pharmaceutical pricing and reimbursement to exchange information and data and to establish a sustainable reporting system for country information. The experience with policies in other countries is highly valuable information for policy makers.
In 2013, the PPRI project was selected by the Executive Agency for Health and Consumers, in collaboration with the Health Programme’s National Focal Points (NFP) and the Directorate General for Health and Consumers (DG SANCO) as a good practice example of an EU Public Health project with an important impact for EU Member States.
In the on-going PPRI initiative, the networking of the competent authorities continues, via regular networking meetings and continuous sharing of relevant information for decision-making, including an up-date of country-specific information.
The Network of Competent Authorities for Pricing and Reimbursement (CAPR)
The CAPR Network was created in 2008 by EU/EEA Member States following the recommendations of the High Level Pharmaceutical Forum for a continuation of cooperation and sharing of experiences. Based on a voluntary membership, the network is designed as an informal cooperation and a strategic and bridge building platform for the Member States. It is intended to exchange experience and information on decision making in the area of pricing and reimbursement of pharmaceuticals. While the competence of the Member States in the area is maintained, the network contributes to their efficient decision making by providing a place to address high level topics of common interest. It also relies on the knowledge gathered from other initiatives with EU/EEA relevance EUnetHTA, PPRI and others.
The membership of the forum includes the authorities/bodies of the Member States that are vested by national laws to make administrative decisions in the area, and the competent Directorates of the European Commission.
The meeting of Competent Authorities on Pricing and Reimbursement takes place with every EU presidency and brings policymakers and decision-makers from all member states together to share knowledge and explore common positions concerning developments in medicines and the pricing of medicines. The Commission acts as a facilitator of these meetings providing administrative and financial support (grant agreement).